Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations

被引：0
|
作者：
Huang, J. [1 ]
Huang, W. [2 ]
Wang, Q. [3 ]
Zhang, C. [1 ]
Ni, S. [4 ]
Sun, D. [4 ]
Zhou, Y. [4 ]
Hou, T. [4 ]
Sun, W. [4 ]
Chen, Z. [4 ]
Wu, Y. -L. [1 ]
机构：
[1] Guangdong Prov Peoples osp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Pathol, Guangzhou, Peoples R China
[3] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China
[4] Burning Rock Biotech, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
EGFR/TP53/RB1; CNV gain; decision tree;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.05
引用
收藏
页码：S48 / S48
页数：1
相关论文
共 50 条
  • [1] Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients
    Chen, H.
    Yuan, S.
    Chen, L.
    Shi, X.
    Wang, L.
    Dong, X.
    Wang, M.
    Wang, A.
    Liu, W.
    Cui, Z.
    Chen, C.
    Mei, L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S587 - S588
  • [2] Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations
    Offin, M.
    Tenet, M.
    Shen, R.
    Rekhtman, N.
    Rizvi, H.
    Hellmann, M.
    Arcila, M.
    Ladanyi, M.
    Rudin, C.
    Kris, M.
    Yu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S412 - S412
  • [3] Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations.
    Wang, Jun
    Chen, Gang
    Zhang, Bicheng
    Sun, Jianguo
    Liang, Jing
    Liu, Xiaolin
    Li, Yan
    Wang, Baocheng
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas
    Watanabe, T
    Yokoo, H
    Yokoo, M
    Yonekawa, Y
    Kleihues, P
    Ohgaki, H
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (12): : 1181 - 1189
  • [5] Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
    Offin, Michael
    Chan, Joseph M.
    Tenet, Megan
    Rizvi, Hira A.
    Shen, Ronglai
    Riely, Gregory J.
    Rekhtman, Natasha
    Daneshbod, Yahya
    Quintanal-Villalonga, Alvaro
    Penson, Alexander
    Hellmann, Matthew D.
    Arcila, Maria E.
    Ladanyi, Marc
    Pe'er, Dana
    Kris, Mark G.
    Rudin, Charles M.
    Yu, Helena A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1784 - 1793
  • [6] The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds
    Duan, Xiaohui
    Cai, Yi
    He, Tingting
    Shi, Xiaoliang
    Zhao, Juan
    Zhang, Hui
    Shen, Yao
    Zhang, Hongjian
    Zhang, Heng
    Duan, Wenbin
    Jiang, Bo
    Mao, Xianhai
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (04) : 1786 - 1796
  • [7] A Pan-Cancer Assessment of RB1/TP53 Co-Mutations
    Cai, Ling
    DeBerardinis, Ralph J.
    Xiao, Guanghua
    Minna, John D.
    Xie, Yang
    CANCERS, 2022, 14 (17)
  • [8] Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
    Hou, Helei
    Qin, Kang
    Liang, Yu
    Zhang, Chuantao
    Liu, Dong
    Jiang, Haiping
    Liu, Kewei
    Zhu, Jingjuan
    Lv, Hongying
    Li, Tianjun
    Zhang, Xiaochun
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 5665 - 5675
  • [9] TP53 Mutations are Present in Targeted NGS Profiles from EGFR Wild type, NSCLC Patients with Poor Prognosis
    Mellet, H.
    Jackson, L.
    Hahn, W.
    Dupuis, N.
    Weaver, A.
    Greer, J.
    Pestano, G.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 1012 - 1012
  • [10] Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy
    Lu, Yiyu
    Li, Zhihua
    Zhu, Huawei
    Zhao, Juan
    Xu, Mian
    Gu, Weiguang
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (12) : 12886 - 12893
12345